Targeting tau degradation: a viable therapeutic approach?
Lancet Neurol
.
2023 Jun;22(6):462-464.
doi: 10.1016/S1474-4422(23)00108-4.
Epub 2023 Apr 5.
Authors
Matthew Mason
1
,
Mehtap Bacioglu
2
,
Giorgio Vivacqua
3
,
Maria Grazia Spillantini
2
,
Aviva M Tolkovsky
2
Affiliations
1
Department of Clinical Neuroscience, University of Cambridge, Cambridge, CB2 0AH, UK. Electronic address: mm2458@cam.ac.uk.
2
Department of Clinical Neuroscience, University of Cambridge, Cambridge, CB2 0AH, UK.
3
Microscopic and Ultrastructural Anatomy Research Unit-Integrated Research Centre (PRABB), Campus Biomedico University of Rome, Rome, Italy.
PMID:
37030317
DOI:
10.1016/S1474-4422(23)00108-4
No abstract available
Publication types
Comment
MeSH terms
Alzheimer Disease* / drug therapy
Humans
Tauopathies*
tau Proteins
Substances
tau Proteins